http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022035147-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_581265968346f63692c94fc23fc6bae3
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-14
filingDate 2021-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c3071ea28d10f530ae11b8572908593
publicationDate 2022-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022035147-A1
titleOfInvention Pharmaceutical composition for oral administration, containing (meta)arsenite salt for inhibiting hair loss and promoting hair growth in patient with alopecia that includes alopecia caused by chemotherapy or radiotherapy in cancer patients
abstract The present invention contains a (meta)arsenite salt as an active ingredient, and thus provides excellent hair loss prevention or hair growth promotion effects on: patients with common alopecia caused by overactivity of androgenic hormones, hypersecretion of sebum, poor blood circulation, scalp dysfunction due to peroxides or bacteria, genetic factors, aging, stress and the like; and alopecia in cancer patients in which hair loss is caused by chemotherapy or radiotherapy for cancer treatment. The described composition according to the present invention enables cancer to be overcome with only a single effect and, when co-administered as an adjuvant in other cancer therapies, can prevent hair loss during cancer treatment while improving cancer treatment effects, and thus can increase overall anti-cancer treatment effects and prevent cancer patients from becoming stressed by hair loss caused by anti-cancer treatment.
priorityDate 2020-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20120048706-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20080030559-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20090122348-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20020083458-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395500
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19649

Total number of triples: 22.